| Description |
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression[1].
|
| Related Catalog |
|
| Target |
OSBPL7[1] ABCA1[1]
|
| In Vitro |
OSBPL7-IN-1 (compound G or Cpd G; 1-10 µM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux[1].
|
| In Vivo |
OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease[1]. Animal Model: Female Balb/c mice induced by Adriamycin (ADR)[1] Dosage: 100 mg/kg Administration: Oral gavage; daily; for 28 days Result: Normalized proteinuria, and significantly reduced renal fibrosis and renal functional decline.
|
| References |
[1]. Matthew B Wright, et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun. 2021 Aug 2;12(1):4662.
|
